Bayer AGA stronger pipeline and new financing give Bayer room to manoeuvre — but investors are still watching one issue: the US glyphosate litigation.
A stronger pipeline and new financing give Bayer room to manoeuvre — but investors are still watching one issue: the US glyphosate litigation.